Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Comparative Study
Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
To assess the cost-effectiveness of oral capecitabine compared with intravenous bolus 5-fluorouracil/leucovorin (5-FU/LV) in the adjuvant treatment of stage III colon cancer in Taiwan from payer (Bureau of National Health Insurance [BNHI]) perspectives. ⋯ From the perspectives of the BNHI and society in Taiwan, capecitabine not only saves costs but also improves health outcomes compared with 5-FU/LV in the adjuvant treatment of stage III colon cancer.
-
To estimate the prevalence of constipation concomitant to opioid treatment and related resource use and costs from the private payer perspective. ⋯ Patients with constipation coincident with opioid treatment exhibited a significantly higher economic burden than did patients without the condition. These results indicate that reducing opioid-induced constipation could lead to potential cost savings for the health care system.
-
The objective of this study is to perform an economic evaluation analyzing the treatment with atorvastatin and simvastatin in comparison to placebo treatment, within the Brazilian Public Healthcare System (SUS) scenario, for patients with high risk of cardiovascular disease; analyzing if the additional cost related to statin treatment is justified by the clinical benefits expected, in terms of cardiovascular event and mortality reduction. ⋯ This study is an important tool for public decision makers. The study can be used in the decision process of increasing cardiovascular disease treatment access with budgetary sustainability for Ministry of Health. In comparison to placebo, the results show that sinvastatin is a cost saving strategy while atorvastatin is not cost effective.
-
Japan has the highest smoking prevalence among the G7 countries, and the Japanese government is expanding tobacco control measures, such as financial support for nicotine replacement therapy and cigarette price increases, to reduce smoking. In 2006, we examined intended quit attempts using hypothetical questions. Since then, a price increase for cigarettes has been proposed and has come closer to being realized. ⋯ The shift of preference for intended attempts to quit is diverse according to nicotine dependence. These differences may be derived from the variations of their time and risk preference and their trust in the tobacco price policies.